ArticleFrontiers in immunology2025
Serum proteomics analysis of lung transplant patients receiving different induction therapies.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lung transplantation in 2025: a narrative review of progress, challenges, and the road ahead.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Induction therapy is widely used in lung transplantation to control the host alloresponse, reducing acute cellular rejection and improving graft survival. Despite its use, data on the biological effects of different induction agents remain limited. Methods: This study examines serum proteomics profiles in lung transplant patients receiving alemtuzumab, anti-thymocyte globulin (ATG), or no induction therapy. Adult lung transplant recipients who underwent transplantation between 2007 and 2013 at the Medical University of Vienna were included. Using mass spectrometry (MS), serum samples were examined before transplantation (T1) and 12 months post-transplant (T2). Results: Among 102 patients (50 alemtuzumab, 34 ATG, 18 no induction), we identified significantly differentially expressed proteins over time and between groups at T2. In the alemtuzumab group, 40 proteins were differentially expressed (3 upregulated, 37 downregulated), in ATG, 22 proteins (3 upregulated, 19 downregulated), and none in the no-induction group. At T2, two proteins (fibulin-1 and fetuin-B) were downregulated between alemtuzumab and no induction, with no significant differences between alemtuzumab and ATG or ATG and no induction. Discussion: Our findings suggest alemtuzumab may have a stronger effect on circulating proteome. Further studies are warranted to elucidate the underlying mechanisms and explore potential clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.